Assignee
PRINCIPIA BIOPHARMA INC
US·48 granted patents·47 pending applications·407 citations·filing 2008–2025
Top patents by PatentIndex Score
95 records- 0199US8673925B1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Mar 18, 2014·114 cites·22 claims
- 0298US9688676B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2017·Granted Jun 27, 2017·32 cites·3 claims
- 0398US9090621B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Jul 28, 2015·29 cites·8 claims
- 0498US8759358B1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Jun 24, 2014·22 cites·16 claims
- 0597US8962635B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Feb 24, 2015·17 cites·1 claims
- 0697US8957080B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 17, 2015·19 cites·24 claims
- 0797US8946241B2Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Feb 3, 2015·18 cites·8 claims
- 0896US11827656B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Nov 28, 2023·2 cites·27 claims
- 0996US11369613B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jun 28, 2022·3 cites·3 claims
- 1095US10456403B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 29, 2019·9 cites·17 claims
- 1195US10092569B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Oct 9, 2018·13 cites·10 claims
- 1295US8940744B2Pyrazolopyrimidine compounds as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Jan 27, 2015·26 cites·30 claims
- 1394US9994576B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jun 12, 2018·14 cites·22 claims
- 1493US11225493B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Jan 18, 2022·4 cites·32 claims
- 1593US9266895B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 23, 2016·17 cites·10 claims
- 1692US10828307B2Salts and solid form of a BTK inhibitorPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Nov 10, 2020·3 cites·4 claims
- 1792US10533013B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Jan 14, 2020·8 cites·10 claims
- 1891US11040980B2Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Jun 22, 2021·3 cites·18 claims
- 1990US9567334B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Feb 14, 2017·6 cites·16 claims
- 2089US11078199B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Aug 3, 2021·2 cites·15 claims
- 2189US10485797B2Treatment of pemphigusPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Nov 26, 2019·10 cites·18 claims
- 2288US9572811B2Treatment of dry eyePRINCIPIA BIOPHARMA INC·Filed 2013·Granted Feb 21, 2017·16 cites·9 claims
- 2387US12162882B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Granted Dec 10, 2024·0 cites·11 claims
- 2487US10899760B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jan 26, 2021·2 cites·12 claims
- 2587US9815834B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2015·Granted Nov 14, 2017·4 cites·16 claims
- 2686US2025197402A1Tyrosine Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2785US11154563B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2018·Granted Oct 26, 2021·2 cites·28 claims
- 2884US10538518B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jan 21, 2020·2 cites·7 claims
- 2984US10538517B2Quinolone derivatives as FGFR inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2016·Granted Jan 21, 2020·3 cites·23 claims
- 3084US2024174676A1Pyrazolopyrimidine compounds as kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3183US10294223B2Quinolone derivatives as fibroblast growth factor receptor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2017·Granted May 21, 2019·2 cites·15 claims
- 3281US12336999B2Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Jun 24, 2025·0 cites·20 claims
- 3381US2022370459A1Salts and Solid Form of a BTK InhibitorPRINCIPIA BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3481US2023151012A1Tyrosine kinase inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3579US2024309000A1Process for Preparing an FGFR InhibitorPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 3678US12410176B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Sep 9, 2025·0 cites·1 claims
- 3778US12312370B2Immunoproteasome inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2023·Granted May 27, 2025·0 cites·20 claims
- 3877US9630963B2Quinolone derivatives as fibroblast growth factor inhibitorsPRINCIPIA BIOPHARMA INC·Filed 2014·Granted Apr 25, 2017·3 cites·14 claims
- 3976US2025381193A1Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 4076US2022073522A1Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4175US2021292323A1Quinolone Derivatives as Fibroblast Growth Factor InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4274US12281110B2Processes for preparing an FGFR inhibitorPRINCIPIA BIOPHARMA INC·Filed 2021·Granted Apr 22, 2025·0 cites·19 claims
- 4374US10946008B2Treatment of pemphigusPRINCIPIA BIOPHARMA INC·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 4473US12281120B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 4572US2025368656A1Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 4672US2025221999A1Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 4771US2021171526A1Tyrosine Kinase InhibitorsPRINCIPIA BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 4871US2025099470A1Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 4970US2025262193A1Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia GravisPRINCIPIA BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 5070US2023399330A1Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-YL] Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 95 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →